Get the Stockscreener App
6.09
5.73%
0.33
After Hours:
6.21
0.12
+1.97%
Aura Biosciences Inc stock is traded at $6.09, with a volume of 331.02K.
It is up +5.73% in the last 24 hours and down -5.87% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$5.76
Open:
$5.83
24h Volume:
331.02K
Relative Volume:
1.68
Market Cap:
$378.31M
Revenue:
-
Net Income/Loss:
$-76.41M
P/E Ratio:
-3.1719
EPS:
-1.92
Net Cash Flow:
$-64.56M
1W Performance:
-0.98%
1M Performance:
-5.87%
6M Performance:
+16.44%
1Y Performance:
-27.93%
1-Day Range:
$5.72
$6.14
1-Week Range:
$5.72
$6.2825
52-Week Range:
$4.345
$12.38
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Compare AURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
6.09 | 357.81M | 0 | -76.41M | -64.56M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Resumed | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | H.C. Wainwright | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
Aura Biosciences Inc Stock (AURA) Latest News
How Aura Biosciences Inc. stock reacts to global recession fearsCEO Change & Long-Term Capital Growth Strategies - newser.com
Aura Biosciences Inc. recovery potential after sell offProfit Target & AI Based Trade Execution Alerts - newser.com
News impact scoring models applied to Aura Biosciences Inc.Weekly Trade Recap & Accurate Trade Setup Notifications - newser.com
Can Arunjyothi Bio Ventures Limited Compete Globally or Is It a Local Player OnlyMonthly Performance Summary & Fast Profit Strategies - earlytimes.in
How sentiment analysis helps forecast Aura Biosciences Inc.July 2025 Closing Moves & High Return Stock Watch Alerts - newser.com
Is Aura Biosciences Inc. stock attractive for hedge funds2025 Macro Impact & Verified Momentum Stock Ideas - newser.com
Using AI based signals to follow Aura Biosciences Inc.Earnings Recap Report & Real-Time Volume Triggers - newser.com
Is Aura Biosciences Inc. stock recession proofJuly 2025 PostEarnings & Long Hold Capital Preservation Tips - newser.com
Is Aura Biosciences Inc. showing signs of accumulation2025 Key Lessons & Real-Time Buy Zone Alerts - newser.com
Non Muscle Invasive Bladder Cancer Pipeline 2025: Pioneering - openPR.com
What analysts say about Aura Biosciences Inc stockEconomic Data Impact & Free High Yield Portfolio Picks - earlytimes.in
What drives Aura Biosciences Inc stock priceDividend Stability Analysis & Exceptional Capital Trading - earlytimes.in
Owning 43% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA), - Yahoo Finance
Rhumbline Advisers Reduces Position in Aura Biosciences, Inc. $AURA - Defense World
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aura Biosciences Inc Stock (AURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Elazzouzi Amy | Senior Vice President, Finance |
Aug 18 '25 |
Sale |
6.70 |
7,722 |
51,737 |
86,558 |
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):